… the application of CpG ODNs as immunostimulatory adjuvants… and DNA hydrogel consisting
of SA-conjugated CpG ODN. … for the Care and Use of Laboratory Animals. The protocols for …

… After the tumor model was established, the animals were grouped and administered with …
First of all, only a small proportion of free CpG oligodeoxynucleotide could enter into the DCs. …

… -motif-containing oligodeoxynucleotides (ODNs), which are … that have been most extensively
characterized in animals … and TLR adjuvants in the context of cancer immunotherapy has …

… of antigenic peptide, CpG oligodeoxynucleotides and cationic … ) to carry the unmethylated
CpG adjuvant and OVA antigen … of the B16F10 model animals. Furthermore, approximately half …

… pot method as novel adjuvants for cancer immunotherapy. Cu- and … CpG oligonucleotides,
shows potential in cancer … (PEI) were used as adjuvant in DNA vaccines for HIV treatment. For …

… performed on bacterial DNA and its synthetic mimic, CpG oligodeoxynucleotides (CpG ODN)
[52]. … motifs occur at higher frequency in bacterial and viral DNA than vertebrate DNA [54]. …

… (39, 40) We believe that this “sticky” feature of CpG DNA … types of TLR agonists, including
RNA oligonucleotides and non-… , we used group sizes of 4 animals/group for immunogenicity …

… formulation of DNA vaccines with traditional or molecular adjuvants. … laboratory animals are
principally used for DNA vaccine … [Citation65] A combined CpG/Poly (I:C) adjuvant enhanced …

… The release of inhibitory DNA as host cells die may serve to down-regulate pathologic … in
complete Freund’s adjuvant into the hind footpads of Lewis rats. When animals with EIN were …

Purpose Persistent high-risk human papillomavirus (HPV) infection is the most common
cause of cervical cancer and its precursor lesions. Although prophylactic HPV vaccines have …